Immediate Impact
65 standout
Citing Papers
The present and future of bispecific antibodies for cancer therapy
2024 Standout
The hallmarks of cancer immune evasion
2024 Standout
Works of Xiling Jiang being referenced
FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma
2020
Development of a Target cell-Biologics-Effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting bispecific agents
2018
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Xiling Jiang | 96 | 67 | 115 | 106 | 17 | 430 | |
| Anjaneya Chimalakonda | 112 | 37 | 103 | 34 | 28 | 434 | |
| Hidetoshi Satoh | 136 | 21 | 68 | 152 | 18 | 415 | |
| Darlene J. Elias | 147 | 98 | 105 | 58 | 27 | 490 | |
| Mohan V. Chari | 140 | 33 | 126 | 33 | 19 | 473 | |
| Gary L. Engelmann | 179 | 20 | 58 | 81 | 15 | 415 | |
| An Huang | 165 | 17 | 106 | 58 | 24 | 488 | |
| Sally E. Ford | 93 | 13 | 53 | 86 | 19 | 434 | |
| Caihong Liang | 280 | 27 | 47 | 36 | 16 | 480 | |
| G. Tartarelli | 120 | 38 | 148 | 40 | 18 | 440 | |
| Changming Xie | 192 | 16 | 84 | 94 | 20 | 483 |
All Works
Login with ORCID to disown or claim papers
Loading papers...